Research
A microfluidic fluorescence lifetime screening platform bridges in vitro and in vivo formats and enables discovery of Amyloid β aggregation inhibitors
Nature ·
The Brief
- A microfluidic fluorescence lifetime screening platform is reported on nature.com.
- The platform is described as bridging in vitro and in vivo formats.
- The authors report using it to discover Amyloid β aggregation inhibitors.
Why it matters
It describes a screening method for Amyloid β aggregation inhibitors that connects test-tube and in vivo formats, which may matter to researchers working on amyloid-related drug discovery.
Who’s affected
- researchers in drug discovery and amyloid aggregation
- #microfluidics
- #fluorescence lifetime
- #amyloid beta
- #drug screening
- #aggregation inhibitors